Jump to ContentJump to Main Navigation

Online

149,00 € / $224.00*

* Prices subject to change. Shipping costs will be added if applicable.
Publication Date:
June 2011
ISSN:
2191-0251
DOI:
10.1515/jpem.2011.189

See all formats and pricing

Online
Individual Subscription Online only
Euro [D] 149.00
RRP for USA, Canada, Mexico
US$ 224.00 *
Print
Individual Subscription Online only
Euro [D] 873.00
RRP for USA, Canada, Mexico
US$ 1310.00 *
Print + Online
Individual Subscription Online only
Euro [D] 1048.00
RRP for USA, Canada, Mexico
US$ 1572.00 *
*Prices subject to change. Shipping costs will be added if applicable.

Editor-in-Chief: Zadik, Zvi

Editorial Board Member: Cassorla, Fernando / Cutfield, Wayne / de Muinck Keizer-Schrama, Sabine M.P.F. / Fideleff, Hugo L. / LaFranch, Stephen H. / Lanes M. D., Roberto / Levitsky, Lynne / Lippe, Barbara / Pfäffle, Roland / Root, Allen W. / Rosenfeld, Ron G. / Werther, George / Kiess, Wieland

12 Issues per year

IMPACT FACTOR 2011: 0.875
5-year IMPACT FACTOR: 1.026

VolumeIssuePage

Issues

The effect of glucocorticoid replacement therapy on bone mineral density in children with congenital adrenal hyperplasia

1 / Cengiz Kara1

1Dr. Sami Ulus Obstetrics and Gynecology, Children’s Health and Disease Training and Research Hospital, Ankara, Turkey

Corresponding author: Semra Cetinkaya, 3251. Cadde, 2/28, Yasamkent, Yenimahalle, Ankara 06810, Turkey Phone: +90 505 3884403, Fax: +90 312 3170353

Citation Information: Journal of Pediatric Endocrinology and Metabolism. Volume 24, Issue 5-6, Pages 265–269, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: 10.1515/jpem.2011.189, June 2011

Abstract

Objectives: 1) To evaluate the effects of glucocorticoid (GC) doses on bone mineral density (BMD) in children with congenital adrenal hyperplasia (CAH), 2) Investigate other factors influencing BMD.

Methods: Twenty-six children with CAH and 11 healthy controls included in the study. All of the patients were examined with dual-energy X-ray absorptiometry (DXA) using a Hologic QDR 1000/W densitometer. The metabolic control state, age at diagnosis GC dose (mg/m2/day), pubertal status, 17 hydroxyprogesterone (17 OHP) levels, bone age (BA), and lumber BMD were evaluated in all cases. BMD (g/cm2), BMD z-score corrected to National Standards (cNS-BMD z-score), BMD z-score corrected to BA (cBABMD), bone mineral content (BMC), BMC corrected to puberty (cPBMC), and bone area (BAR) values were determined. Patients were grouped according to mean on-therapy serum 17 OHP levels as tight control (17 OHP<10 nmol/L) (n:13) and poor control (17 OHP>10 nmol/L) (n:13). All groups were compared with each other.

Results: The age range was 2.1–15.7 years and the mean age (±SD) 9.3 (±3.5) years. There were no significant differences between the groups in terms of GC doses, lumbar BMD values [BMD (g/cm2), BMD z-score corrected to National Standards (cNS-BMD z-score), BMD z-score corrected to BA (cBABMD), bone mineral content (BMC), BMC corrected to puberty (cPBMC), and bone area (BAR)]. However, the BMI value was higher in children with CAH than normal healthy controls. The BA of the poor control, late diagnosed groups and male patients were higher than tight control, early diagnosed group and female patients, respectively. BMC and BA were lower than the control group in tight control with early diagnosed patients. The cBABMD z-score was lower in males with poor control than males with tight control. There were no similar results in female patients.

Conclusions: Although GC treatment seems not to influence BMD in CAH patients in our study, further studies are needed to additionally evaluate daily calcium (Ca) intake, polymorphism of vitamin D receptor, ethnic factors (strict Islamic dress, etc.), socioeconomic status, and 24-h urinary free cortisol level.

Keywords: bone mineral density; congenital adrenal hyperplasia; glucocorticoids; Turkish children

Comments (0)

Please log in or register to comment.